Blueprint Medicines/$BPMC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
Ticker
$BPMC
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
685
ISIN
US09627Y1091
Website
BPMC Metrics
BasicAdvanced
$8.3B
-
-$2.45
0.75
-
Price and volume
Market cap
$8.3B
Beta
0.75
52-week high
$128.78
52-week low
$73.04
Average daily volume
5.3M
Financial strength
Current ratio
2.802
Quick ratio
2.618
Long term debt to equity
171.829
Total debt to equity
208.496
Interest coverage (TTM)
-2.16%
Profitability
EBITDA (TTM)
-158.367
Gross margin (TTM)
96.48%
Net profit margin (TTM)
-27.70%
Operating margin (TTM)
-31.01%
Effective tax rate (TTM)
-1.19%
Revenue per employee (TTM)
$820,000
Management effectiveness
Return on assets (TTM)
-9.75%
Return on equity (TTM)
-47.71%
Valuation
Price to revenue (TTM)
14.518
Price to book
24.26
Price to tangible book (TTM)
24.26
Price to free cash flow (TTM)
-54.08
Free cash flow yield (TTM)
-1.85%
Free cash flow per share (TTM)
-237.70%
Growth
Revenue change (TTM)
99.19%
Earnings per share change (TTM)
-48.18%
3-year revenue growth (CAGR)
36.46%
10-year revenue growth (CAGR)
96.59%
3-year earnings per share growth (CAGR)
-39.46%
10-year earnings per share growth (CAGR)
-23.11%
What the Analysts think about BPMC
Analyst ratings (Buy, Hold, Sell) for Blueprint Medicines stock.
Bulls say / Bears say
Sanofi's acquisition of Blueprint Medicines for up to $9.5 billion underscores the strategic value of Blueprint's portfolio, particularly its flagship drug Ayvakit, which generated nearly $150 million in Q1 2025 and is projected to reach $2 billion in annual sales by 2030. (ft.com)
Blueprint Medicines reported a 61% year-over-year increase in net product revenues from Ayvakit, totaling $149.4 million in Q1 2025, and raised its full-year revenue guidance to between $700 million and $720 million, indicating strong market demand and effective commercialization. (tipranks.com)
The company's robust pipeline, including the initiation of the Phase 3 HARBOR trial for elenestinib and the advancement of BLU-808 into proof-of-concept trials for various allergic and inflammatory diseases, positions Blueprint for sustained growth and diversification in the immunology sector. (stocktitan.net)
Despite strong revenue growth, Blueprint Medicines reported a net income of only $0.5 million in Q1 2025, primarily driven by a one-time gain from the sale of an equity investment, indicating potential challenges in achieving consistent profitability. (tipranks.com)
The acquisition by Sanofi, while highlighting Blueprint's value, may lead to integration challenges and potential shifts in strategic direction, which could impact the company's operational efficiency and focus. (reuters.com)
Legal investigations into the fairness of the proposed sale to Sanofi, including concerns about the adequacy of the sale price and potential breaches of fiduciary duties by Blueprint's board, could lead to shareholder dissatisfaction and potential legal complications. (tradingview.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
BPMC Financial Performance
Revenues and expenses
BPMC Earnings Performance
Company profitability
BPMC News
AllArticlesVideos
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Business Wire·3 weeks ago
HAPPY FATHER'S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Blueprint Medicines Corporation (NASDAQ: BPMC)
GlobeNewsWire·4 weeks ago
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Blueprint Medicines stock?
Blueprint Medicines (BPMC) has a market cap of $8.3B as of July 10, 2025.
What is the P/E ratio for Blueprint Medicines stock?
The price to earnings (P/E) ratio for Blueprint Medicines (BPMC) stock is 0 as of July 10, 2025.
Does Blueprint Medicines stock pay dividends?
No, Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders as of July 10, 2025.
When is the next Blueprint Medicines dividend payment date?
Blueprint Medicines (BPMC) stock does not pay dividends to its shareholders.
What is the beta indicator for Blueprint Medicines?
Blueprint Medicines (BPMC) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.